Literature DB >> 8847458

[A clinicopathological study in clear cell adenocarcinoma of the endometrium].

T Yamawaki1, H Teshima, N Takeshima, K Yamauchi, K Hasumi.   

Abstract

We clinicopathologically reviewed cases of clear cell adenocarcinoma (CCA) of the endometrium and adenocarcinoma of the endometrial type mixed with a clear cell component (AMC). 1. Among 1,152 cases of endometrial carcinoma, CCA and AMC were found in 16 (1.4%) and 21 (1.8%) cases, respectively. 2. As revealed by cumulative survival rates based on the Kaplan-Meier method, the prognosis was significantly poorer in CCA and AMC than in endometrial carcinoma (p < 0.001). 3. As for the subtype of CCA, 5 (31%), 9 (56%) and 2 (13%) cases were papillary, solid, and tubulocystic, respectively. 4. The frequency of epithelial hyaline body, bizarre nucleus, psammoma body, necrosis, lymphoplasmacytic infiltration, lymphatic invasion, vessel invasion, and atypical hyperplasia among cases of CCA was 8 (50%), 7 (44%), 5 (31%), 6 (38%), 8 (50%), 5 (36%), 4 (29%) and 1 (7%) cases, respectively. Histologically, lymphoplasmacytic response was the most closely correlated with the prognosis. 5. Among the cases of AMC, there were 6 cases of metastasis and recurrence. In 5 (83%) of these, the clear component increased markedly in metastatic and recurrent lesions although the component was very minor in the primary lesions.

Entities:  

Mesh:

Year:  1996        PMID: 8847458

Source DB:  PubMed          Journal:  Nihon Sanka Fujinka Gakkai Zasshi        ISSN: 0300-9165


  2 in total

1.  Does Preoperative Diagnosis Will Change the Treatment Plan of Clear Cell Carcinoma of Endometrium Masquerading as Desmoid Tumor of Anterior Abdominal Wall?: a Case Report.

Authors:  Sachin S Kadam; Sanjay Deshmukh; S M Karandikar; Tejaswini Kadam
Journal:  Indian J Surg Oncol       Date:  2021-05-26

2.  Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases.

Authors:  Oluwole Fadare; Wenxin Zheng; Marta A Crispens; Howard W Iii Jones; Dineo Khabele; Katja Gwin; Sharon X Liang; Khaled Mohammed; Mohamed M Desouki; Vinita Parkash; Jonathan L Hecht
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.